منابع مشابه
Unique approach for B lymphoma therapy.
Genetic engineering has substantially improved antibodies used in the treatment of cancer and related diseases, initially by providing more compatible reagents (chimeric, humanized, human) for patients but more recently by improving their clinical efficacy.1 In this issue of Blood, Gupta et al have used a novel genetic engineering method, termed “dock and lock,”2-4 to construct a HexAb bispecif...
متن کاملAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...
متن کاملPrimary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
Primary mediastinal B-cell lymphoma (PMBL) is a subtype of diffuse large B-cell lymphoma (DLBCL) that is putatively derived from a thymic B cell. Accounting for up to 10% of cases of DLBCL, this subtype predominantly affects women in the third and fourth decades of life. Its clinical and molecular characteristics are distinct from other subtypes of DLBCL and, in fact, closely resemble those of ...
متن کاملAntibody Therapy of Pediatric B-Cell Lymphoma
B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma the...
متن کاملNanoparticle-based strategy for personalized B-cell lymphoma therapy
B-cell lymphoma is associated with incomplete response to treatment, and the development of effective strategies targeting this disease remains challenging. A new personalized B-cell lymphoma therapy, based on a site-specific receptor-mediated drug delivery system, was developed in this study. Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the anti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2012
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2012-02-409052